Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 489

1.

Human papillomavirus vaccine introduction--the first five years.

Markowitz LE, Tsu V, Deeks SL, Cubie H, Wang SA, Vicari AS, Brotherton JM.

Vaccine. 2012 Nov 20;30 Suppl 5:F139-48. doi: 10.1016/j.vaccine.2012.05.039. Review. Erratum in: Vaccine. 2014 Feb 26;32(10):1225.

PMID:
23199957
2.

A case study using the United Republic of Tanzania: costing nationwide HPV vaccine delivery using the WHO Cervical Cancer Prevention and Control Costing Tool.

Hutubessy R, Levin A, Wang S, Morgan W, Ally M, John T, Broutet N.

BMC Med. 2012 Nov 13;10:136. doi: 10.1186/1741-7015-10-136.

3.

Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.

Poljak M.

Clin Microbiol Infect. 2012 Oct;18 Suppl 5:64-9. doi: 10.1111/j.1469-0691.2012.03946.x. Review.

4.

Implementation of human papillomavirus immunization in the developing world.

Kane MA, Serrano B, de Sanjosé S, Wittet S.

Vaccine. 2012 Nov 20;30 Suppl 5:F192-200. doi: 10.1016/j.vaccine.2012.06.075. Review.

PMID:
23199963
5.

Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.

Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, Sultanov SN, Kosenko IA, Brotons M, Buttmann N, Dartell M, Arbyn M, Syrjänen S, Poljak M.

Vaccine. 2013 Dec 31;31 Suppl 7:H46-58. doi: 10.1016/j.vaccine.2013.06.043.

PMID:
24332297
6.

Prospects and challenges in the introduction of human papillomavirus vaccines in the extended Middle East and North Africa region.

Jumaan AO, Ghanem S, Taher J, Braikat M, Al Awaidy S, Dbaibo GS.

Vaccine. 2013 Dec 30;31 Suppl 6:G58-64. doi: 10.1016/j.vaccine.2012.06.097. Review.

PMID:
24331821
7.

Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014--United States.

Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, Curtis RC, Markowitz L; Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC.; Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2014 Jul 25;63(29):620-4.

8.

Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).

Kim JJ, Sharma M, O'Shea M, Sweet S, Diaz M, Sancho-Garnier H, Seoud M.

Vaccine. 2013 Dec 30;31 Suppl 6:G65-77. doi: 10.1016/j.vaccine.2012.06.096.

PMID:
24331822
9.

Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.

Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny LA.

Vaccine. 2013 Dec 29;31 Suppl 5:F47-52. doi: 10.1016/j.vaccine.2012.06.066. Review.

PMID:
24331747
10.

The Australian experience with the human papillomavirus vaccine.

Garland SM.

Clin Ther. 2014 Jan 1;36(1):17-23. doi: 10.1016/j.clinthera.2013.12.005. Review.

PMID:
24417782
11.

Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.

Poljak M, Seme K, Maver PJ, Kocjan BJ, Cuschieri KS, Rogovskaya SI, Arbyn M, Syrjänen S.

Vaccine. 2013 Dec 31;31 Suppl 7:H59-70. doi: 10.1016/j.vaccine.2013.03.029. Review.

PMID:
24332298
12.

Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States.

Centers for Disease Control and Prevention (CDC)..

MMWR Morb Mortal Wkly Rep. 2013 Jul 26;62(29):591-5.

13.

Costs of introducing and delivering HPV vaccines in low and lower middle income countries: inputs for GAVI policy on introduction grant support to countries.

Levin A, Wang SA, Levin C, Tsu V, Hutubessy R.

PLoS One. 2014 Jun 26;9(6):e101114. doi: 10.1371/journal.pone.0101114.

14.

Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.

Kim JJ, Campos NG, O'Shea M, Diaz M, Mutyaba I.

Vaccine. 2013 Dec 29;31 Suppl 5:F60-72. doi: 10.1016/j.vaccine.2012.07.093.

PMID:
24331749
15.

Post-licensure monitoring of HPV vaccine in the United States.

Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF.

Vaccine. 2010 Jul 5;28(30):4731-7. doi: 10.1016/j.vaccine.2010.02.019. Review.

PMID:
20188681
16.

An overview on the implementation of HPV vaccination in Europe.

Bonanni P, Levi M, Latham NB, Bechini A, Tiscione E, Lai P, Panatto D, Gasparini R, Boccalini S.

Hum Vaccin. 2011 Jan-Feb;7 Suppl:128-35. Review.

PMID:
21245659
17.

Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.

Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT.

Vaccine. 2008 Dec 2;26(51):6529-41. doi: 10.1016/j.vaccine.2008.08.067. Review.

PMID:
18805453
18.

Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases.

Bosch FX, Tsu V, Vorsters A, Van Damme P, Kane MA.

Vaccine. 2012 Nov 20;30 Suppl 5:F1-11. doi: 10.1016/j.vaccine.2012.05.090. Review.

PMID:
23199951
19.

Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study.

Gertig DM, Brotherton JM, Budd AC, Drennan K, Chappell G, Saville AM.

BMC Med. 2013 Oct 22;11:227. doi: 10.1186/1741-7015-11-227.

20.

Introduction of a National HPV vaccination program into Bhutan.

Dorji T, Tshomo U, Phuntsho S, Tamang TD, Tshokey T, Baussano I, Franceschi S, Clifford G.

Vaccine. 2015 Jul 17;33(31):3726-30. doi: 10.1016/j.vaccine.2015.05.078.

PMID:
26057136

Supplemental Content

Support Center